- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04095468
Organ-preserving Management in Patients With Complete or Near-complete Tumour Response After Preoperative Radio(Chemo)Therapy for Rectal Cancer
Watch-and-wait strategy in rectal cancer is gaining momentum. There is a large variability in reporting the proportion of patients achieving clinical complete response (cCR) after routinely delivered preoperative radio(chemo)therapy, likely because of patients' selection. This proportion in population-based level is poorly defined. In addition, predictive factors for cCR are also poorly defined. It is known that cCR response is observed often in small tumours. However, cCR proportion in large cancers has not been sufficiently evaluated. For example, even though pathological complete response (pCR) does occur in large fixed cancer, it is unknown whether cCR does also occur because persistent fibrous stroma may mimic residual cancer in all of such cases.
This is a prospective observational population-based cohort study on low rectal cancer to answer the question of how often clinical or near-clinical tumour response occur after routinely delivered preoperative radiotherapy in relation to the pre-treatment tumour characteristics. The additional question was how often pCR occur in relation to the pre-treatment tumour characteristics in the patients managed by total mesorectal excision because of persistent tumour after radiotherapy. The additional aim was the implementation of watch-and-wait strategy or full-thickness local excision (as an option instead of total mesorectal excision in the patients with sustained near-cCR) within a frame of a prospective study. In the patients managed by organ preservation, the secondary outcome measures were: i) local regrowth rate, ii) effectiveness of salvage surgery, iii) disease-free survival at 3 years and overall survival at 5 years, iv) anorectal function.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Krzysztof Bujko, M.D. PhD
- Phone Number: +48601207466
- Email: Krzysztof.Bujko@coi.pl
Study Locations
-
-
-
Bydgoszcz, Poland
- Recruiting
- Collegium Medicum Nicolaus Copernicus University and Oncology Centre
-
Contact:
- Michał Jankowski, M.D.
-
Principal Investigator:
- Michał Jankowski, M.D.
-
Kielce, Poland
- Recruiting
- Regional Oncological Centre
-
Contact:
- Jacek Sadowski, M.D.
-
Principal Investigator:
- Jacek Sadowski, M.D.
-
Kraków, Poland
- Not yet recruiting
- Jagiellonian Medical University College
-
Contact:
- Piotr Richter, M.D.
-
Principal Investigator:
- Piotr Richter, M.D.
-
Lublin, Poland
- Recruiting
- St. John's Cancer Center
-
Contact:
- Małgorzata Jankiewicz, M.D.
-
Principal Investigator:
- Małgorzata Jankiewicz, M.D.
-
Wrocław, Poland
- Recruiting
- Silesian Oncological Centre
-
Contact:
- Jolanta Szelachowska, M.D.
-
Principal Investigator:
- Jolanta Szelachowska, M.D.
-
Zamość, Poland
- Recruiting
- NU-MED Centre for Cancer Diagnosis and Treatment
-
Contact:
- Marek Mazurek, M.D.
-
Principal Investigator:
- Marek Mazurek, M.D.
-
-
Mazovian
-
Warsaw, Mazovian, Poland, 02-781
- Recruiting
- Maria Skłodowska-Curie Institute - Oncology Center
-
Contact:
- Krzysztof Bujko, M.D. PhD
- Phone Number: +48601207466
- Email: Krzysztof.Bujko@coi.pl
-
Principal Investigator:
- Krzysztof Bujko, M.D. PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Primary rectal cancer
- Low tumour (accessible by digital rectal examination)
- Routine preoperative radio(chemo)therapy according to the institutional policy; short-course radiation and immediate surgery is not allowed.
- Informed consent for watch-and-wait strategy or local excision in patients with cCR and near-cCR
Exclusion Criteria:
- Recurrent cancer
- Cancers situated in the upper rectum
- Distant metastases
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Resectable rectal cancer
|
Preoperative radiotherapy +/- chemotherapy, then surgery (total mesorectal excision) or watch-and-wait
|
Rectal cancer with threatened mesorectal fascia
|
Preoperative radiotherapy +/- chemotherapy, then surgery (total mesorectal excision) or watch-and-wait
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentages of cCR and near-cCR in the patients with "resectable" cancer
Time Frame: 11 weeks from the start of radiotherapy
|
11 weeks from the start of radiotherapy
|
|
Percentages of cCR and near-cCR in the patients with threatened mesorectal fascia.
Time Frame: 11 weeks from the start of radiotherapy
|
11 weeks from the start of radiotherapy
|
|
Percentages of cCR and near-cCR in relation to the selected tumour characteristics.
Time Frame: 11 weeks from the start of radiotherapy
|
The selected tumour characteristics: TN categories, tumour length, degree of circumferential involvement, tumour mobility on digital rectal examination (mobile, tethered, fixed) and status of mesorectal fascia (threatened or not).
|
11 weeks from the start of radiotherapy
|
Percentages of pCR in the patients after total mesorectal excision performed because of tumour persistence.
Time Frame: 12 weeks from the start of radiotherapy
|
12 weeks from the start of radiotherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 5 years
|
5 years
|
|
Disease-free survival
Time Frame: 3 years
|
3 years
|
|
Local regrowth rate
Time Frame: 5 years
|
5 years
|
|
Anorectal function assessed by low anterior resection syndrome (LARS) score
Time Frame: 3 years
|
The questionnaire will be completed by patients.
It includes 5 items related to anorectal function.
The range of the score (0-42) is divided into 0 to 20 (no LARS), 21 to 29 (minor LARS) and 30 to 42 (major LARS).
|
3 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ORGANPRESERV1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Cancer
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage... and other conditionsUnited States
-
OHSU Knight Cancer InstituteNatera, Inc.RecruitingEstablishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
Jonsson Comprehensive Cancer CenterNatera, Inc.; The Joseph Drown FoundationRecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8 | Locally...United States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...United States
-
City of Hope Medical CenterWithdrawnRecurrent Rectal Cancer | Stage I Rectal Cancer | Stage II Rectal Cancer | Stage III Rectal Cancer
Clinical Trials on Preoperative Radio(Chemo)Therapy
-
Technische Universität DresdenGerman Cancer Research Center; National Center for Tumor Diseases, Heidelberg; Radiation Oncology Working Group of the German Cancer Society and other collaboratorsRecruitingHead-and-neck Squamous Cell CarcinomaGermany
-
Rigshospitalet, DenmarkActive, not recruitingQuality of Life | Pain | Oropharynx Cancer | Human Papilloma Virus | Swallowing Disorder | Saliva AlteredDenmark
-
MVZ Leopoldina GmbHCompleted
-
Medical University of GrazUnknownLymphoproliferative Disorders | Psoriasis | Eczema | Pruritus | Vitiligo | Cutaneous T Cell Lymphoma | Mastocytosis | Graft Vs Host Disease | Lichen Planus | Prurigo | Polymorphic Light EruptionAustria
-
Centre Georges Francois LeclercCompletedAdvanced Rectal CancersFrance
-
Institut Claudius RegaudCompleted
-
Universitätsklinikum KölnZKS KölnWithdrawnCervical Cancer ≥ FIGO IIB and or Lymph Node Metastases
-
Maastricht Radiation OncologyCompleted
-
Xinhua Hospital, Shanghai Jiao Tong University...Active, not recruiting
-
Samsung Medical CenterTerminatedLocally Advanced Rectal CancerKorea, Republic of